Long-term survival of type XVII collagen revertant cells in an animal model of revertant cell therapy

Journal of Investigative Dermatology

Volumn 134, Issue 2, 2014, Pages 571-574

  Gostyński, Antoni ^a   Llames, Sara ^b   García, Marta ^c,d   Escamez, María J ^c   Martinez Santamaria, Lucía ^c,d   Nijenhuis, Miranda ^a   Meana, Alvaro ^b   Pas, Hendri H ^a   Larcher, Fernando ^c   Pasmooij, Anna M G ^a   Jonkman, Marcel F ^a   Del Rio, Marcela ^c,d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c CIEMAT   (Spain)

^d UNIVERSIDAD CARLOS III DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 17; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

CELL EXPANSION; CELL MUTANT; CELL SURVIVAL; CELL THERAPY; HAIR FOLLICLE; IN VITRO STUDY; KERATINOCYTE; LETTER; LONG TERM SURVIVAL; NONHUMAN; PRIORITY JOURNAL; REVERTANT CELL; REVERTANT CELL THERAPY; UPREGULATION;

ANIMALS; AUTOANTIGENS; CELL TRANSPLANTATION; CELLS, CULTURED; GRAFT SURVIVAL; HUMANS; KERATINOCYTES; MICE; MICE, NUDE; MODELS, ANIMAL; MOSAICISM; NON-FIBRILLAR COLLAGENS; SKIN TRANSPLANTATION;

EID: 84892797256     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.308     Document Type: Letter

References (14)

1. Duheron V, Hess E, Duval M et al. (2011) Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. Proc Natl Acad Sci USA 108:5342-7
2. Garcia M, Escamez MJ, Carretero M et al. (2007) Modeling normal and pathological processes through skin tissue engineering. Mol Carcinog 46:741-5
3. Gostynski A, Deviaene FC, Pasmooij AM et al. (2009) Adhesive stripping to remove epidermis in junctional epidermolysis bullosa for revertant cell therapy. Br J Dermatol 161:444-7
4. Hamill KJ, Hopkinson SB, Jonkman MF et al. (2011) Type XVII collagen regulates lamellipod stability, cell motility, and signaling to Rac1 by targeting bullous pemphigoid antigen 1e to alpha6beta4 integrin. J Biol Chem 286:26768-80
5. Jonkman MF, Pasmooij AM (2009) Revertant mosaicism-patchwork in the skin. N Engl J Med 360:1680-2
6. Jonkman MF, Scheffer H, Stulp R et al. (1997) Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell 88:543-51
7. Llames S, Garcia E, Garcia V et al. (2006) Clinical results of an autologous engineered skin. Cell Tissue Bank 7:47-53
8. Llames SG, Del Rio M, Larcher F et al. (2004) Human plasma as a dermal scaffold for the generation of a completely autologous bioengineered skin. Transplantation 77:350-5
9. Pasmooij AM, Jonkman MF (2012) First symposium on natural gene therapy of the skin. Exp Dermatol 21:236-9
10. Pasmooij AM, Nijenhuis M, Brander R et al. (2012) Natural gene therapy may occur in all patients with generalized non-herlitz junctional epidermolysis bullosa with COL17A1 mutations. J Invest Dermatol 132:1374-83
11. Pasmooij AM, Pas HH, Deviaene FC et al. (2005) Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa. Am J Hum Genet 77:727-40
12. Van den Bergh F, Eliason SL, Burmeister BT et al. (2012) Collagen XVII (BP180) modulates keratinocyte expression of the proinflammatory chemokine, IL-8. Exp Dermatol 21:605-11
13. Yuen WY (2012) Chapter 11. new versatile monoclonal antibodies against type XVII collagen endodomain that distinguish type XVII collagen-related epidermolysis bullosa subytpes. In: Junctional Epidermolysis Bullosa (Thesis). Groningen, The Netherlands, pp 185-202
14. Yuspa SH, Kilkenny AE, Steinert PM et al. (1989) Expression of murine epidermal differentiation markers is tightly regulated by restricted extracellular calcium concentrations in vitro. J Cell Biol 109:1207-17